Recent Updates
Recently added Catalysts
XENE

Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

Key Takeaway: BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences: Jefferies Biotech on the Bay

Full Press Release Details

BURNABY, British Columbia, April 25, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company today announced that Xenon’s management team will participate in the following investor conferences:
Jefferies Biotech on the Bay Summit
Date/Location: April 26-27, 2022 in Miami, FL (one-on-one investor meetings only)
Bloom Burton & Co. Healthcare Investor Conference 2022
Date/Location: May 2-3, 2022 at the Metro Toronto Convention Centre in Toronto, ON
Presentation: Tuesday, May 3, 2022
Time: 11:30 am Eastern Time
2022 RBC Capital Markets Global Healthcare Conference
Date/Location: May 17-18, 2022 at the InterContinental Barclay in New York, NY
Fireside Chat: Wednesday, May 18, 2022
Time: 11:00 am Eastern Time
Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Xenon Pharmaceuticals Inc.
Last updated: Apr 25, 2022